CD8A and pancreatic ductal adenocarcinoma: These findings are consistent with Das et al. [33], who concluded that neutralizing IL-1ß could promote intratumoral CD8 + T cell infiltration and function and sensitize pancreatic ductal adenocarcinoma to checkpoint immunotherapy.